KIM-1 AND NGAL AS BIOMARKERS OF NEPHROPATHY IN TYPE II DIABETES.

Crossref Cited-by Linking logo

  • Abstract
  • References
  • How to Cite This Article
  • Corresponding Author

Background: clinically detectable diabetic nephropathy is based on albumin excretion and glomerular filtration rate that mainly reflects the glomerular damage. New biomarkers have arisen with the promise of detecting kidney damage prior to the currently used markers. Objectives: to assess the usefulness of the urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the early diagnosis of diabetic kidney disease in type2 diabetes mellitus and to estimate their relation to the degree of nephropathy in comparison to the level of albuminuria and other parameters. Design: cross sectional study. Setting: the internal medicine department - al-zahraa university hospital and endocrinology department - helwan university hospital from 2014 / 2015. Patients and methods: seventy diabetic patients were chosen and divided into 3 subgroups (normoalbuminuric, microalbuminuric and macroalbuminuric), compared to 19 healthy controls. For all participants, clinical examination, urine analysis, fasting and 2hours post prandial serum glucose, glycated hemoglobin a1c%, serum cholesterol, triglycerides, serum creatinine, urea, estimated glomerular filtration rate, urinary albumin to creatinine ratio, urinary kim-1 and ngal were done. Results: both urinary ngal and kim-1 correlated positively with urinary albumin, disease duration and hba1c. Ukim-1 correlated negatively with estimated glomerular filtration rate. The cutoff point to differentiate the normoalbuminuric group from control for ukim-1 was 88.5ng/l. The diagnostic sensitivity was 91.6%, diagnostic specificity was 84%. At the cutoff value 3.25 ?g/l for ungal the diagnostic sensitivity was 100%, diagnostic specificity was 89.4%. Conclusion: ukim-1 and ungal are sensitive and specific markers for detection of diabetic nephropathy in patients with type2 diabetes mellitus.

  1. Elsherbiny NM, Al-Gayyar MM. The role of IL-18 in type 1 diabetic nephropathy: the problem and future treatment. Cytokine. 2016; 81:15?22.
  2. Bonventre JV. ?Can we target tubular damage to prevent renal function decline in diabetes?? Seminars in Nephrology. 2012; l. (32) 5: 452?562.
  3. De Carvalho JA,?Tatsch E,?Hausen BS,?Bollick YS,?Moretto MB,?Duarte T,? et al. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type2 diabetes. Clinical Biochemistry.?2016; 49(3):232? 236.
  4. Rysz J,?Gluba-Brz?zka A,?Franczyk B,?Jabłonowski Z,?and?Ciałkowska-Rysz Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. Int J Mol Sci. 2017; 18(8).
  5. Xinghua Shao, Lei Tian, Weijia Xu, Zhen Zhang, Chunlin Wang, Chaojun Qi, et al.?Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One. 2014 Jan 3; 9(1):e84131.
  6. Tang SCW and Lai KN. The pathogenic role of the renal proximal tubular cell in diabetic nephropathy.?Nephrology Dialysis Transplantation. 2012; 27(8) 3049?3056
  7. FisehaT?and?Tamir Urinary Markers of Tubular Injury in Early Diabetic Nephropathy. Int J Nephrol. 2016; (4): 647-685.
  8. Eilenberg W, Stojkovic S, Piechota-Polanczyk A, Kaun C, Rauscher S, Groger M, et al. Neutrophil gelatinase-associated lipocalin (NGAL) is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro. Eur J VascEndovasc Surg. 2016; 51(5):623?31.
  9. Bonventre Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrology Dialysis Transplantation 2009; 24(11) 3265?268.
  10. American Diabetes Association. Diabetes Care?2013;?36(1):? 67-74.
  11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.?Nephron.?1976 16: 31?41.
  12. Zeng XF,?Lu DX,?Li JM1,?Tan Y,?Li Z,?Zhou L,?et al. Performance of urinary neutrophil gelatinase-associated lipocalin, clusterin, and cystatin C in predicting diabetic kidney disease and diabetic microalbuminuria: a consecutive cohort study. BMC Nephrol. 2017; 18: 233.
  13. Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy.?BiochemBiophys Res Commun.?2013; 433(4):359?361
  14. Currie G, McKay G, Delles C. Biomarkers in diabetic nephropathy: present and future. World J Diabetes. 2014; 5:763-776.
  15. Young Oh M,?Lee H,? Kim JS,? Ryu W,? Lee SH ,? Ko S,? et al. Cystatin C, a novel indicator of renal function, reflects severity of cerebral microbleeds. BMC Neurol. 2014; 14:1.
  16. Moriya T, Omura K, Matsubara M,?Yoshida Y, Hayama Kand Motoshi Ouchi. Arteriolar Hyalinosis Predicts Increase in Albuminuria and GFR Decline in Normo- and Microalbuminuric Japanese Patients With Type2 Diabetes. Diabetes Care.?2017; 40(10):1373-1378.
  17. Kundu D ,? Roy A,? Mandal T,? Bandyopadhyay U,? Ghosh E,? Ray D. Relation of microalbuminuria to glycosylated hemoglobin and duration of type 2 diabetes.?Niger J ClinPract.?2013; 16 (2):216?20

18.??? Jacek Z, Jolanta S, Piotr F, Katarzyna L, Witold S, Bogda Z, et al. Normal-Range Albuminuria Does Not Exclude Nephropathy in Diabetic Children. Pediatric Nephrology. 2010; 25, 1445-1451

  1. Lacquaniti A,?Donato V,?Pintaudi B,?Di Vieste G,?Chirico V,?Buemi A, et al. Normoalbuminuric diabetic nephropathy. tubular damage and NGAL. ActaDiabetol. 2013; 50:935-42.
  2. Assal H, ? Tawfeek S,?Rasheed E,?El-Lebedy D ,?and? Thabet Serum Cystatin C and Tubular Urinary Enzymes as Biomarkers of Renal Dysfunction in Type 2 Diabetes Mellitus. Endocrinology and Diabetes.2013 ;( 6)7?13.
  3. Wu J,?Shao X, Lu K,?Zhou J,?Ren M,?Xie X,?et al. Urinary RBP and NGAL Levels are Associated with Nephropathy in Patients with Type 2 Diabetes. Cell PhysiolBiochem 2017; 42:594?602
  4. Thrailkill KM, Moreau C. S, Cockrell GE. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus.?Endocrine.?2010; 37(2):336?343.
  5. Bolignano D,?Lacquaniti A,?Coppolino G,?Donato V,?Fazio MR,?Nicocia G, et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res. 2009; 32:91-8.
  6. Ahmed SA and Hamed MA. Kidney injury molecule-1 as a predicting factor for inflamed kidney, diabetic and diabetic nephropathy Egyptian patients. Journal of Diabetes & Metabolic Disorders. 2015; 14:6.
  7. Katz R,?Bonventre JV,?Sabbisetti V,?Siscovick D,?Sarnak M,?Shlipak MG. The Associations of Urinary Levels of Kidney Injury Molecule-1 (KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL) with Kidney Function Decline in the Multi-Ethnic Study of Atherosclerosis (MESA).?Am J Kidney Dis 2012; 60(6):904-11.
  8. Zhang Z, Humphreys BD, Bonventre JV. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxta-membrane region. J Am SocNephrol. 2013; 18: 2704-2714.
  9. van Timmeren MM,?van den Heuvel MC,?Bailly V,?Bakker SJ,?van Goor H,?Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol. 2007; 212(2):209-17.
  10. Kondaveeti S,?Kumaraswamy D, Mishra Sh,?Aravind Kumar R,?and?Shaker? Evaluation of glycated albumin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus. J ClinDiagnRes. 2013; 7 (7):1280?1283.
  11. Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? SeminNephrol 2012; 32: 452-62.
  12. Solak İbrahim, Bulgurlu SS, Demirtunc R. The relation between HBA1c and urine albumin excretion in type 2 diabetes mellitus patients. Diabetic ActaMedicaMediterranea, 2017, 33: 65
  13. Berhane A, Well J, Knowler W, Nelson R, Hanson R. eGFR predict kidney failure in Pima Indians with type 2 diabetes mellitus. Clin J. Am So. Nephroloct. 2011; 6 (10):2444-2451.

Samia I. Ali, Amal A. Morsy, Rehab A. Mohammed and Hebat-Allah E. Gelany. (2018); KIM-1 AND NGAL AS BIOMARKERS OF NEPHROPATHY IN TYPE II DIABETES., Int. J. of Adv. Res., 6 (02), 1412-1417, ISSN 2320-5407. DOI URL: https://dx.doi.org/10.21474/IJAR01/6571

Rehab A. Mohammed
Department of Internal Medicine, AlAzhar University, Cairo, Egypt

DOI:

Article DOI: 10.21474/IJAR01/6571      
DOI URL: https://dx.doi.org/10.21474/IJAR01/6571

Download Full Paper

Download PDF No. of Downloads: 84 | No. of Views: 269